who manufactures glp-1 drugs GLP-1s in the “Barbecue Belt Buckle” GLP-1s and the Unintended Consequences
Description
Clinical eligibility is defined by a diagnosis of obesity, diabetes or overweight with other present risk factors
If no evidence of retinopathy is found and glycemic control is stable, examinations every 1-2 years may be considered
Higher gauge means thinner needle
Like Mounjaro, it reduces caloric intake through GLP-1 and GIP receptor activation
Conclusions GLP-1 agonists reduce fetal survival, weight, growth and skeletal ossification and can induce major congenital anomalies
